产品名称 (−)-Huperzine A - LKT Labs
产品货号 H8162
产品价格 现货询价,电话:010-67529703
产品规格
产品品牌 lktlabs
产品概述
产品详情 (−)-Huperzine A

Description

Huperzine A (HupA) is a sesquiterpene alkaloid derived from the fir-like moss Huperzia serrata; it exhibits anticonvulsant/antiepileptic, neuromodulatory, cognition enhancing, neuroprotective, and antinociceptive activities. HupA acts as a reversible, selective acetylcholinesterase (AChE) inhibitor and is being explored in clinical trials as a potential treatment for Alzheimer’s Disease. Several studies have shown HupA to improve cognition, memory, mood, and/or daily activities at a range of doses. Additionally, HupA’s comparatively long-lasting binding of AChE is protective against organophosphate-induced seizure and status epilepticus. In cellular and animal models, this compound exhibits non-competitive, reversible antagonist activity at NMDA receptors. HupA is also under examination as a potential non-dependence-inducing antinociceptive, as it blocks chemical, thermal, and mechanical pain stimulation in vivo.

Product Info

Cas No.

102518-79-6

Purity

≥97%

Formula

C15H18N2O

Formula Wt.

242.32

Chemical Name

1-amino-13-ethylidene-11-methyl-6-aza-tricyclo- [7.3.1.02,7]trideca-2(7),3,10-trien-5-one

Synonym

HupA

Melting Point

214-215°C

Solubility

Soluble in DMSO, ethanol, methanol, and aqueous acids.

Appearance

White Crystal Powder

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

Info Sheet

H8162 Info Sheet PDF

References

Yu D, Thakor DK, Han I, et al. Alleviation of chronic pain following rat spinal cord compression injury with multimodal actions of huperzine A. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):E746-55. PMID: 23386718.

Rafii MS, Walsh S, Little JT, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011 Apr 19;76(16):1389-94. doi: PMID: 21502597.

Park P, Schachter S, Yaksh T. Intrathecal huperzine A increases thermal escape latency and decreases flinching behavior in the formalin test in rats. Neurosci Lett. 2010 Feb 5;470(1):6-9. PMID: 20026382.

Zhang Z, Wang X, Chen Q, et al. Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi. 2002 Jul 25;82(14):941-4. PMID: 12181083.

Gordon RK, Nigam SV, Weitz JA, et al. The NMDA receptor ion channel: a site for binding of Huperzine A. J Appl Toxicol. 2001 Dec;21 Suppl 1:S47-51. PMID: 11920920.

Camps P, El Achab R, Morral J, et al. New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease. J Med Chem. 2000 Nov 30;43(24):4657-66. PMID: 11101357.

Lallement G, Veyret J, Masqueliez C, et al. Efficacy of huperzine in preventing soman-induced seizures, neuropathological changes and lethality. Fundam Clin Pharmacol. 1997;11(5):387-94. PMID: 9342591.

Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li Xue Bao. 1995 Sep;16(5):391-5. PMID: 8701750.

产品资料